Shots:
- Dren Bio has partnered with Sanofi to discover & develop next-generation B-cell depleting therapy for the treatment of various autoimmune diseases
- As per the deal, Dren Bio will receive $100M upfront & ~$1.7B in milestones, with both parties jointly leading discovery & preclinical work using Dren Bio’s platform, after which Sanofi will handle development, manufacturing, regulatory & commercialization efforts
- Also, Dren Bio has the option to enter a US profit/loss share with Sanofi &, if exercised, would co-fund 40% of global development in exchange for US co-promotion rights & a 50/50 US profit/loss split, while retaining eligibility for ex-US milestones & tiered royalties
Ref: Dren Bio | Image: Dren Bio & Sanofi |Press Release
Related News: ADEL and Sanofi Ink ~$1.04B Global Licensing Deal for ADEL-Y01
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
